Amgen Inc(AMGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low424.74
Day High434.51
Open:430.36
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Faeth Therapeutics (FTH)
Tipranks
Amgen Fine-Tunes Evenity Delivery in New Phase 1 Study
Zacks Investment Research
Bet on These Healthcare ETFs to Benefit From the Aging US Population
Bet on These Healthcare ETFs to Benefit From the Aging US Population
Tipranks
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Bristol-Myers Squibb (BMY) and Neurocrine (NBIX)
Zacks Investment Research
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down
Tipranks
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and United Therapeutics (UTHR)
Tipranks
Bank of America Securities Remains a Sell on Amgen (AMGN)
WealthUp
4 Best ETFs for the Rest of 2026
ETF with candlestick chart_Image by bigjom jom via Shutterstock
Tipranks
Amgen’s Monthly Diabetes Shot Takes Aim at Semaglutide in New Phase 3 Trial
Zacks Investment Research
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?
Tipranks
Amgen (AMGN) Gets a Hold from Cantor Fitzgerald
Tipranks
Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)
Tipranks
Morgan Stanley Issues a Hold Rating on Amgen (AMGN)
Tipranks
Amgen’s AMG 513 Obesity Trial Reaches Phase 1 Completion, Adding a New Angle to the Weight-Loss Drug Race
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
StockStory
2 Nasdaq 100 Stocks Worth Investigating and 1 We Question
AMZN
Tipranks
Amgen’s Evolocumab Study Signals Quiet Efficiency Gains for Cholesterol Franchise
Tipranks
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Arcturus Therapeutics (ARCT)
Tipranks
Amgen’s Pediatric Psoriasis Study in Japan Wraps Up, Setting the Stage for Otezla Growth

Profile

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.
Market data provided by Barchart. Exchange delay details and data provider terms here. Information may be delayed, is provided 'as is' and is solely for informational purposes, and not for trading, investment or advice.